News

 

16th June, 2009

Diabetology Limited Nominated as One of 15 Most Innovative Healthcare Businesses by the HiT World Innovation Summit 2009

Diabetology Limited is pleased to announce that it has been nominated as one of the 15 most innovative healthcare businesses by the HiT World Innovation Summit 2009.

The upcoming HiT World Innovation Summit (which will be held in Barcelona on the 17th-19th June) has focused on three global industries with exceptional growth potential - healthcare, telecom and cleantech - and across these industries they have selected 15 of the most innovative healthcare companies, of which Diabetology is one of them.

Through its nomination Diabetology has been invited to give a presentation and will be given an exhibition stand at the conference.  The presentation will be given on 18th June in the session starting at 11:30.

Selection has also brought with it:

·         Free of charge office space in Barcelona for 12 months

·         Potential to qualify for the 2009 European Venture Summit

·         Potential to be shortlisted for the 2009 European Venture Contest, with a €90,000 prize

NOTES TO EDITORS

About Diabetology Limited

Diabetology is a specialty biopharmaceutical company employing a proprietary oral delivery system to administer known bioactives as well as novel compounds for the comprehensive management of diabetes.

Diabetology's lead project is Capsulin, an oral encapsulated formulation of recombinant human insulin for the treatment of patients with type 1 and type 2 diabetes. Diabetology intends to develop Capsulin both as a novel oral anti-diabetic agent for the treatment of patients with type 2 diabetes (Capsulin OAD) and as a replacement to injectable insulin for patients suffering from type 1 and type 2 diabetes (Capsulin IR).

The company’s innovative drug delivery technology, Axcess™ Oral Drug Delivery System, significantly increases the absorption of peptides, proteins and other macromolecules across the intestinal wall when delivered orally without any chemical modification of the active compounds.  It is based on a simple mixture of components consisting entirely of registered pharmacopoeial or GRAS excipients with a long history of pharmaceutical use. The absorption enhancing activities obtained from the formulation of these excipients is entirely novel and forms the basis of five international patent applications.  Diabetology has licensed exclusive rights to Axcess™ for the formulation of oral therapies for diabetes.

About HiT Barcelona World Innovation Summit 2009

HiT Barcelona is a unique global event bringing together leading innovators, experts, entrepreneurs and investors to share and expand knowledge and to promote strategic business projects via tournaments. Focused on three key sectors with a high growth potential, Telecom, CleanTech and Healthcare, HiT Barcelona combines top-level plenary sessions (Plenary Congress) with a programme of meetings and sector-specific competitions of some of the most innovative business projects worldwide (Innovation Marketplaces). The event will also host the first ever truly international “Business-Plan/Early-Stage” competition for entrepreneurs, the Global Entrepreneurship Competition.

HiT Barcelona is an initiative of the Spanish Ministry of Industry, Commerce and Tourism, the Autonomous Government of Catalonia, the Barcelona City Council (via their Finance, Economy and Innovation Departments), the Barcelona Chamber of Commerce and La Caixa.  It is organised by the Fira de Barcelona and the Barcelona Plà Estrategic. The first edition of the event is expected to bring to Barcelona over 2,500 delegates from the 17th to the 19th of June 2009.

ENDS

For more information contact:

Timothy P. Broke-Smith
Corporate Development Officer
Diabetology Limited

Tel: +44 (0)20 7193 8363
Email: t.broke-smith@diabetology.co.uk